公开(公告)号：US06678240B2

公开(公告)日：2004-01-13

申请号：US10247270

申请日：2002-09-19

Applicant: Bernd Geh ,  Paul Gräupner ,  Klaus Wurmbrand ,  Thomas Stammler ,  Dirk Stenkamp ,  Jochen Stühler

Inventor： Bernd Geh ,  Paul Gräupner ,  Klaus Wurmbrand ,  Thomas Stammler ,  Dirk Stenkamp ,  Jochen Stühler

IPC: G03B2732

CPC classification number: G03F7/706 ,  G01M11/0207 ,  G01M11/0242 ,  G01M11/0257 ,  G02B27/0012 ,  G03F7/70225 ,  G03F7/70258 ,  G03F7/70666

Abstract: In order to optimize the image properties of several optical elements of which at least one is moved relative to at least one stationary optical element, the overall image defect resulting from the interaction of all optical elements is first of all measured. This is represented as a linear combination of the base functions of an orthogonal function set. The movable element is then moved to a new measurement position and the overall image defect is measured once again. After the linear combination representation of the new overall image defect, the image defects of the movable element and of the stationary element are calculated from the data thereby obtained. With only one movable optical element a target position in which the overall image defect is minimized can be directly calculated and adjusted there from. If several movable optical elements are available, methods are given for the efficient determination of the respective target position.

Abstract translation: 为了优化其中至少一个相对于至少一个固定光学元件移动的多个光学元件的图像特性，首先测量由所有光学元件的相互作用产生的整体图像缺陷。 这被表示为正交函数集的基函数的线性组合。 然后将可移动元件移动到新的测量位置，并再次测量整个图像缺陷。 在新的整体图像缺陷的线性组合表示之后，根据获得的数据计算可移动元件和静止元件的图像缺陷。 只有一个可移动光学元件可以直接计算和调整整个图像缺陷最小化的目标位置。 如果有多个可移动的光学元件可用，则给出用于有效确定各个目标位置的方法。

公开(公告)号：US08916599B2

公开(公告)日：2014-12-23

申请号：US13119834

申请日：2009-09-25

Applicant: Roland Pfau ,  Kirsten Arndt ,  Henri Doods ,  Norbert Hauel ,  Klaus Klinder ,  Raimund Kuelzer ,  Juergen Mack ,  Henning Priepke ,  Dirk Stenkamp

Inventor： Roland Pfau ,  Kirsten Arndt ,  Henri Doods ,  Norbert Hauel ,  Klaus Klinder ,  Raimund Kuelzer ,  Juergen Mack ,  Henning Priepke ,  Dirk Stenkamp

IPC: A61K31/4184 ,  C07D235/30 ,  C07D417/12 ,  C07D401/14 ,  C07D263/58 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D403/12 ,  C07D471/04 ,  C07D277/82

CPC classification number: C07D235/30 ,  C07D263/58 ,  C07D277/82 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

Abstract translation: 提供式（I）化合物，其中R1，R6，R8，Q2，Q3，Q3a，Q4，L和A具有说明书中给出的含义及其药学上可接受的盐，该化合物可用于治疗 需要和/或需要MAPEG家族成员的活性抑制，特别是治疗炎症和/或癌症的疾病。

公开(公告)号：US20130303571A1

公开(公告)日：2013-11-14

申请号：US13942077

申请日：2013-07-15

Applicant: Roland PFAU ,  Kirsten ARNDT ,  Henri DOODS ,  Klaus KLINDER ,  Raimund KUELZER ,  Dimitrijs LUBRIKS ,  Juergen MACK ,  Benjamin PELCMAN ,  Henning PRIEPKE ,  Robert ROENN ,  Dirk STENKAMP ,  Edgars SUNA

Inventor： Roland PFAU ,  Kirsten ARNDT ,  Henri DOODS ,  Klaus KLINDER ,  Raimund KUELZER ,  Dimitrijs LUBRIKS ,  Juergen MACK ,  Benjamin PELCMAN ,  Henning PRIEPKE ,  Robert ROENN ,  Dirk STENKAMP ,  Edgars SUNA

IPC: C07D235/30 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

CPC classification number: C07D235/30 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

Abstract: The present invention relates to compounds of general formula I in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

Abstract translation: 本发明涉及其中A，L，M，Q2，Q3，Q4，R 1，R 5，R a，R b，R c，W，X，Y，Z 1，Z 2，Z 3在说明书中定义的通式I化合物 ，其盐，特别是其生理上可接受的盐。 该化合物在治疗和/或预防炎性疾病和相关病症，特别是治疗和/或预防疼痛中具有潜在的用途。 本发明还涉及这些化合物作为药物，含有它们的药物组合物及其制备的用途。

公开(公告)号：US20130237515A1

公开(公告)日：2013-09-12

申请号：US13780343

申请日：2013-02-28

Applicant: Thorsten OOST ,  Ralf LOTZ ,  Dirk STENKAMP

Inventor： Thorsten OOST ,  Ralf LOTZ ,  Dirk STENKAMP

IPC: C07D401/12 ,  C07D401/14 ,  C07D213/69 ,  C07D413/12 ,  C07D237/16

CPC classification number: C07D401/12 ,  C07D213/69 ,  C07D237/16 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D413/10 ,  C07D413/12

Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2, L1, L2, U and B are as defined in the application, which have valuable pharmacological properties, and in particular modulate the activity of the MCH receptor.

Abstract translation: 本发明涉及通式I的化合物，其中基团R1，R2，L1，L2，U和B如申请中所定义，其具有有价值的药理学性质，特别是调节MCH受体的活性。

公开(公告)号：US20120309755A1

公开(公告)日：2012-12-06

申请号：US13314574

申请日：2011-12-08

Applicant: Henning Priepke ,  Henri Doods ,  Raimund Kuelzer ,  Roland Pfau ,  Dirk Stenkamp ,  Benjamin Pelcman ,  Robert Roenn ,  Dimitrijs Lubriks ,  Edgars Suna

Inventor： Henning Priepke ,  Henri Doods ,  Raimund Kuelzer ,  Roland Pfau ,  Dirk Stenkamp ,  Benjamin Pelcman ,  Robert Roenn ,  Dimitrijs Lubriks ,  Edgars Suna

IPC: C07D471/04 ,  A61K31/5377 ,  A61P29/00 ,  A61K31/437

CPC classification number: C07D471/04

Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, Ra, Rb have meanings given in the description.

Abstract translation: 本发明涉及式I化合物，其用作微粒体前列腺素E2合酶-1（mPGES-1）的抑制剂，含有它们的药物组合物及其作为用于治疗和/或预防炎性疾病及相关病症的药物的用途。 A，L，M，W，R 1，R 2，R 3，R 4，R 6，R 7，R a，R b具有说明书中给出的含义。

公开(公告)号：US08278336B2

公开(公告)日：2012-10-02

申请号：US12743013

申请日：2008-11-21

Applicant: Dirk Gottschling ,  Georg Dahmann ,  Henri Doods ,  Annekatrin Heimann ,  Stephan Georg Mueller ,  Klaus Rudolf ,  Gerhard Georg Schaenzle ,  Dirk Stenkamp

Inventor： Dirk Gottschling ,  Georg Dahmann ,  Henri Doods ,  Annekatrin Heimann ,  Stephan Georg Mueller ,  Klaus Rudolf ,  Gerhard Georg Schaenzle ,  Dirk Stenkamp

IPC: A61K31/44 ,  C07D213/62 ,  C07D213/78 ,  C07D213/72

CPC classification number: C07D401/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to new CGRP-antagonists of general formulae Ia and Ib wherein R1, R2, R3, R4 and R5 are defined as mentioned below, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Abstract translation: 本发明涉及通式Ia和Ib的新CGRP拮抗剂，其中R 1，R 2，R 3，R 4和R 5如下所定义，互变异构体，异构体，非对映异构体，对映异构体，水合物，混合物和 其盐以及盐的水合物，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途及其制备方法。

公开(公告)号：US20120208839A1

公开(公告)日：2012-08-16

申请号：US13211471

申请日：2011-08-17

Applicant: Henning PRIEPKE ,  Henri DOODS ,  Raimund KUELZER ,  Roland PFAU ,  Dirk STENKAMP ,  Benjamin PELCMAN ,  Robert ROENN ,  Dimitrijs LUBRIKS ,  Edgars SUNA

Inventor： Henning PRIEPKE ,  Henri DOODS ,  Raimund KUELZER ,  Roland PFAU ,  Dirk STENKAMP ,  Benjamin PELCMAN ,  Robert ROENN ,  Dimitrijs LUBRIKS ,  Edgars SUNA

IPC: A61K31/437 ,  A61P29/00 ,  C07D471/04

CPC classification number: C07D471/04

Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R6, R7 have meanings given in the description.

Abstract translation: 本发明涉及式I化合物，其用作微粒体前列腺素E2合酶-1（mPGES-1）的抑制剂，含有它们的药物组合物及其作为用于治疗和/或预防炎性疾病及相关病症的药物的用途。 A，M，W，R 1，R 2，R 6，R 7具有在说明书中给出的含义。

公开(公告)号：US20120165304A1

公开(公告)日：2012-06-28

申请号：US13130663

申请日：2009-11-26

Applicant: Stephan-Georg Mueller ,  Christopher John Brown ,  Alexander Heifetz ,  Bernd Nosse ,  Juergen Prestle ,  Natacha Prevost ,  Klaus Rudolf ,  Stefan Scheuerer ,  Marcus Schindler ,  Dirk Stenkamp ,  Leo Thomas ,  Heather Tye

Inventor： Stephan-Georg Mueller ,  Christopher John Brown ,  Alexander Heifetz ,  Bernd Nosse ,  Juergen Prestle ,  Natacha Prevost ,  Klaus Rudolf ,  Stefan Scheuerer ,  Marcus Schindler ,  Dirk Stenkamp ,  Leo Thomas ,  Heather Tye

IPC: A61K31/55 ,  C07D491/107 ,  A61K31/551 ,  A61P3/00 ,  A61P25/00 ,  C07D487/14 ,  C07D495/04

CPC classification number: C07D487/14

Abstract: The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

Abstract translation: 本发明涉及由式（I）定义的化合物，其中基团X，Y，W和R 1至R 4如权利要求1所定义，具有有价值的药理活性。 特别地，这些化合物是5-HT 2C受体的激动剂，因此适用于治疗和预防可被受体抑制影响的疾病，如代谢和CNS相关疾病。

公开(公告)号：US20120088755A1

公开(公告)日：2012-04-12

申请号：US13140607

申请日：2009-12-17

Applicant: Dirk Gottschling ,  Henri Doods ,  Annekatrin Heimann ,  Stephan Georg Mueller ,  Klaus Rudolf ,  Gerhard Schaenzle ,  Dirk Stenkamp

Inventor： Dirk Gottschling ,  Henri Doods ,  Annekatrin Heimann ,  Stephan Georg Mueller ,  Klaus Rudolf ,  Gerhard Schaenzle ,  Dirk Stenkamp

IPC: A61K31/551 ,  C07D471/04 ,  C07D498/20 ,  C07D401/14 ,  A61K31/538 ,  A61K31/506 ,  A61K31/537 ,  A61P29/00 ,  A61P25/06 ,  C07D413/14 ,  C07D405/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D471/04 ,  C07D498/20

Abstract: The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

Abstract translation: 本发明涉及通式I的新化合物，其中A，U，V，X，Y，R 1，R 2和R 3如下文所定义，互变异构体，其异构体，非对映体，对映异构体，水合物， 其混合物和盐以及盐，特别是其生理上可接受的盐与无机或有机酸或碱的水合物，含有这些化合物的药物，其用途和制备方法。

公开(公告)号：US20120010185A1

公开(公告)日：2012-01-12

申请号：US13239537

申请日：2011-09-22

Applicant: Dirk STENKAMP ,  Stephan Georg MUELLER ,  Gerald Juergen ROTH ,  Joerg KLEY ,  Klaus RUDOLF ,  Armin HECKEL ,  Marcus SCHINDLER ,  Ralf LOTZ ,  Thorsten LEHMANN-LINTZ

Inventor： Dirk STENKAMP ,  Stephan Georg MUELLER ,  Gerald Juergen ROTH ,  Joerg KLEY ,  Klaus RUDOLF ,  Armin HECKEL ,  Marcus SCHINDLER ,  Ralf LOTZ ,  Thorsten LEHMANN-LINTZ

IPC: A61K31/4427 ,  C07D213/69 ,  C07D413/10 ,  C07D403/10 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4412 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/513 ,  A61K31/501 ,  A61K31/4725 ,  A61P25/00 ,  A61P3/04 ,  A61P3/00 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P3/06 ,  A61P19/02 ,  A61P25/24 ,  A61P25/22 ,  A61P25/08 ,  A61P25/28 ,  A61P13/00 ,  A61P25/30 ,  C07D401/10

CPC classification number: C07D401/14 ,  C07D213/63 ,  C07D213/69 ,  C07D213/74 ,  C07D237/14 ,  C07D237/16 ,  C07D239/52 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/06 ,  C07D403/10 ,  C07D405/14 ,  C07D409/14 ,  C07D417/12 ,  C07D451/06 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Abstract translation: 本发明涉及通式I的化合物，其中基团B，k，L，U，V，W，X，Y，Z，R 1，R 2具有权利要求1中给出的含义。此外，本发明涉及 含有至少一种本发明化合物的药物组合物。 由于它们的MCH受体拮抗活性，本发明的药物组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症，食欲过剩，厌食症，食欲过盛和糖尿病。